Low Normal Cerebrospinal Fluid A-beta-42 Levels Predict Clinical Progression in Nondemented Subjects

Betty M. Tijms; Daniela Bertens; Rosalinde E. Slot; Alida A. Gouw; Charlotte E. Teunissen; Philip Scheltens; Wiesje M. van der Flier; Pieter Jelle Visser

doi:10.1002/ana.24921

Low Normal Cerebrospinal Fluid A-beta-42 Levels Predict Clinical Progression in Nondemented Subjects

Betty M. Tijms^*, Daniela Bertens, Rosalinde E. Slot, Alida A. Gouw, Charlotte E. Teunissen, Philip Scheltens, Wiesje M. van der Flier, Pieter Jelle Visser

^*Corresponding author for this work

MHeNs - Cognitive Neuropsychiatry and Clinical Neuroscience

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid beta 1-42 (>= 640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p <0.05; mild cognitive impairment: HR = 0.19, p <.01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid beta 1-42 levels within the normal range into account.

Original language	English
Pages (from-to)	749-753
Number of pages	5
Journal	Annals of Neurology
Volume	81
Issue number	5
DOIs	https://doi.org/10.1002/ana.24921
Publication status	Published - May 2017

Keywords

MILD COGNITIVE IMPAIRMENT
ALZHEIMERS ASSOCIATION WORKGROUPS
BETA-AMYLOID 42
DIAGNOSTIC GUIDELINES
NATIONAL INSTITUTE
DISEASE
BIOMARKERS
DEMENTIA
TAU
RECOMMENDATIONS

Access to Document

10.1002/ana.24921

Cite this

@article{f676f7e46e8f4365b03aefb8384d4d68,

title = "Low Normal Cerebrospinal Fluid A-beta-42 Levels Predict Clinical Progression in Nondemented Subjects",

abstract = "We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid beta 1-42 (>= 640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p <0.05; mild cognitive impairment: HR = 0.19, p <.01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid beta 1-42 levels within the normal range into account.",

keywords = "MILD COGNITIVE IMPAIRMENT, ALZHEIMERS ASSOCIATION WORKGROUPS, BETA-AMYLOID 42, DIAGNOSTIC GUIDELINES, NATIONAL INSTITUTE, DISEASE, BIOMARKERS, DEMENTIA, TAU, RECOMMENDATIONS",

author = "Tijms, {Betty M.} and Daniela Bertens and Slot, {Rosalinde E.} and Gouw, {Alida A.} and Teunissen, {Charlotte E.} and Philip Scheltens and {van der Flier}, {Wiesje M.} and Visser, {Pieter Jelle}",

year = "2017",

month = may,

doi = "10.1002/ana.24921",

language = "English",

volume = "81",

pages = "749--753",

journal = "Annals of Neurology",

issn = "0364-5134",

publisher = "Wiley",

number = "5",

}

TY - JOUR

T1 - Low Normal Cerebrospinal Fluid A-beta-42 Levels Predict Clinical Progression in Nondemented Subjects

AU - Tijms, Betty M.

AU - Bertens, Daniela

AU - Slot, Rosalinde E.

AU - Gouw, Alida A.

AU - Teunissen, Charlotte E.

AU - Scheltens, Philip

AU - van der Flier, Wiesje M.

AU - Visser, Pieter Jelle

PY - 2017/5

Y1 - 2017/5

N2 - We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid beta 1-42 (>= 640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p <0.05; mild cognitive impairment: HR = 0.19, p <.01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid beta 1-42 levels within the normal range into account.

AB - We studied whether continuous lower normal cerebrospinal fluid (CSF) amyloid beta 1-42 (>= 640pg/ml) levels were related with rate of clinical progression in a sample of 393 nondemented memory clinic patients. Lower normal levels were associated with faster clinical progression, and this depended on baseline cognitive status (subjective cognitive decline: hazard ratio [HR] = 0.57, p <0.05; mild cognitive impairment: HR = 0.19, p <.01), indicating that normal CSF amyloid levels do not exclude incident Alzheimer disease. These findings suggest that research on preclinical markers for Alzheimer disease should take the continuum of CSF amyloid beta 1-42 levels within the normal range into account.

KW - MILD COGNITIVE IMPAIRMENT

KW - ALZHEIMERS ASSOCIATION WORKGROUPS

KW - BETA-AMYLOID 42

KW - DIAGNOSTIC GUIDELINES

KW - NATIONAL INSTITUTE

KW - DISEASE

KW - BIOMARKERS

KW - DEMENTIA

KW - TAU

KW - RECOMMENDATIONS

U2 - 10.1002/ana.24921

DO - 10.1002/ana.24921

M3 - Article

SN - 0364-5134

VL - 81

SP - 749

EP - 753

JO - Annals of Neurology

JF - Annals of Neurology

IS - 5

ER -